Wastewater treatment has become quintessential in recent times as environmental degradation caused by inadequate or no wastewater management poses a substantial threat to economic activity and human and animal health. With the surging awareness regarding the potential threats of inadequate wastewater treatment, countries across the world are adopting microfiltration technologies. Water treatment plants are increasingly opting for microfiltration membranes due to their proven economic efficiency and high performance.
Moreover, the growing pharmaceutical industry will help the microfiltration membrane market witness a CAGR of 9.0% during the forecast period (2020–2030). According to P&S Intelligence, the market generated revenue of $2,885.57 million in 2019, and it is projected to generate $7,517.38 million revenue by 2030. Pharmaceutical companies are extensively using polypropylene (PP), polyethersulfone (PES), and polyvinylidene fluoride (PVDF) microfiltration membranes for the filtration of proteins and preservatives, due to their exceptional retention characteristics, high flow rate, and low protein binding feature.
Additionally, the surging health issues arising from the intake of toxic beverages and food items will boost the adoption of microfiltration membranes, as they help in separating the contaminants from such edible products. Thus, the burgeoning demand for unadulterated and uncontaminated food items and drinks will encourage the adoption of microfiltration technologies by food and beverage companies in the coming years. In addition, the oil and gas, biotechnology, dairy, and semiconductor and electronics sectors use microfiltration membranes in abundance.
The type segment of the microfiltration membrane market is classified into cellulose, polyimide, PP, PES, PVDF, polyether ether ketone (PEEK), and polytetrafluoroethylene (PTFE). Among these, the PVDF category held the largest market share in 2019 due to the ability of PVDF microfiltration membranes to offer high flow rates for solvent-based and mobile phase applications, such as multiplexed bead-based assays and sample preparation. Owing to these advantages, a huge quantity of such membranes is being used in the pharmaceutical industry for protein separation.
All such microfiltration membranes are manufactured by Alfa Laval AB, SUEZ, Asahi Kasei Corporation, Culligan International Company, Applied Membranes Inc., Markel Corporation, Graver Technologies LLC, Toray Industries Inc., 3M Company, Koch Membrane Systems Inc., and Merck KGaA. Currently, these companies are majorly opting for mergers and acquisitions to widen their customer base. For instance, in October 2019, DuPont De Nemours Inc. acquired Memcor, the membrane business unit of Evoqua Water Technologies LLC, to expand its profit margins. Memcor offers membrane biofiltration and ultrafiltration technologies to customers across the world.
Therefore, the booming demand for treated water and growing consumption of uncontaminated and unadulterated food and drinks will augment the usage of microfiltration membranes in the foreseeable future.
Synder Filtration is proud to announce a 23% increase in top line revenue in 2012.
Our core business in spiral wound membranes and membrane systems continue to show strong growth across many industries.
Last fall, we initiated plans to expand our research & development, system fabrication, pilot testing and engineering departments.
Since then, we have finalized the purchase of a new 53,000 square foot building adjacent to Synder headquarters, and plan to complete the expansion by Q3 2013.
The new facility will provide ample room for growth for years to come.
To our new and existing valued customers: we sincerely thank you for a great year in 2012 and we look forward to growing our relationship and further mutual success in 2013.
